Cytosorbents (CTSO) Shares Outstanding (Weighted Average) (2010 - 2026)

Cytosorbents (CTSO) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $62.7 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 3.3% year-over-year to $62.7 million; the trailing twelve-month figure through Mar 2026 stood at $62.7 million (up 3.3% YoY), and the FY2025 full-year result was $62.2 million, up 14.32% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $62.7 million, up from $62.2 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $62.7 million in Q1 2026 and bottomed at $2.7 million in Q4 2023.
• The 5-year median for Shares Outstanding (Weighted Average) is $54.3 million (2024), against an average of $49.2 million.
• The widest annual swing landed in 2023, when Shares Outstanding (Weighted Average) plunged 93.79%; it then soared 1911.21% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $43.6 million in 2022, then slumped by 93.79% to $2.7 million in 2023, then jumped by 1911.21% to $54.4 million in 2024, then rose by 14.32% to $62.2 million in 2025, then increased by 0.81% to $62.7 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $62.7 million (Q1 2026), $62.2 million (Q4 2025), and $62.0 million (Q3 2025), per Business Quant data.

Peer Comparison